TIDMRGT 
 
28 January 2011 
 
                             ReGen Therapeutics Plc 
                           ("ReGen" or the "Company") 
 
                           Result of General Meeting 
 
The  board of ReGen announces  that, at the general  meeting held earlier today, 
all resolutions were duly passed. 
 
As  stated in the circular sent  to shareholders on 12 January 2011, the passing 
of resolutions 3, 4 & 5 is dependent on receipt of a confirmation order from the 
High Court of Justice of England and Wales (the "Confirmation Order") at a court 
hearing  that is due  to take place  on 16 February 2011. A further announcement 
will be issued in due course. 
 
Percy Lomax, Chairman, commented: "The Directors are delighted that shareholders 
have  unanimously  passed  all  resolutions.  We  are  now  looking  forward  to 
implementing  the  investment  objectives  of  Alexander  David  Investments Plc 
following approval by the High Court." 
 
 
Subject to receipt of the Confirmation Order: 
 
 i. the  Company will  be reclassified  as an  investing company pursuant to AIM 
    Rule  15, under the terms  of which the  Company will have until 20 February 
    2012, being 12 months from the date on which the Demerger becomes effective, 
    to  implement  its  investment  policy,  as  detailed  in the aforementioned 
    circular.  Otherwise, trading in the Company's  shares would be suspended at 
    7:30 a.m.  on  21 February  2012. The  Company  would  remain  provisionally 
    suspended  for six months, following which, if it would remain the case that 
    the Company fails to undertake a reverse takeover or otherwise implement its 
    investing  policy,  it  would  be  proposed  to  cancel the admission of the 
    Company's shares with effect from 7:00 a.m. on 21 August 2012. 
 
 
 ii. the Company will be renamed Alexander David Investments Plc; 
 
 
 iii. David  Scott  and  Michael  Hicks  will  be  appointed as directors of the 
      Company; and 
 
 
 iv. Timothy Shilton, Martin Small and Peter Garrod will resign from the board. 
 
 
 
For the avoidance of doubt, the timetable of future principal events with regard 
to the Demerger is as follows: 
 
Last  day of dealings in  ReGen Ordinary Shares on              10 February 2011 
AIM cum entitlement to participate in the Demerger 
 
 
Record  Time for  the purposes  of determining the 6.00 p.m. on 14 February 2011 
Shareholders   entitled   to  participate  in  the 
Demerger and the grant of New Warrants 
 
 
Bonus Issue                                                     15 February 2011 
 
 
Court Hearing to confirm Reduction of Capital                   16 February 2011 
 
 
Reduction of Capital becomes effective                          17 February 2011 
 
 
Expected date of the Demerger                                   18 February 2011 
 
 
Change  of  name  of  ReGen  Therapeutics  Plc  to              18 February 2011 
Alexander David Investments Plc 
 
 
CREST accounts credited with NewCo Shares                       18 February 2011 
 
 
Posting of share certificates for the NewCo Shares               By 8 March 2011 
to certificated Shareholders 
 
 
Posting   of  warrant  certificates  for  the  New               By 8 March 2011 
Warrants to Shareholders 
 
 
Definitions of all defined terms referred to above are available in the circular 
sent  to shareholders  on 12 January  2011, which is  available at the Company's 
website at www.regentherapeutics.com. 
 
 
 
Enquiries: 
 
 ReGen Therapeutics Plc               +44 20 7153 4920 
 Percy Lomax 
 
 
 Cairn Financial Advisers LLP         +44 20 7148 7900 
 Nominated Adviser 
 Liam Murray / Avi Robinson 
 
 
 Alexander David Securities Limited   +44 20 7448 9820 
 Broker 
 David Scott / Nick Bealer 
 
 
 
 
 
 
 
 
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: ReGen Therapeutics Plc via Thomson Reuters ONE 
 
[HUG#1483422]
Argent Biopharma (LSE:RGT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Argent Biopharma Charts.
Argent Biopharma (LSE:RGT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Argent Biopharma Charts.